Quanterix to acquire Akoya Biosciences.

Quanterix, a company fueling scientific discovery through ultra-sensitive biomarker detection, agreed to acquire Akoya Biosciences, a biotechnology company in Marlborough, Massachusetts. Under the terms of the agreement, Quanterix will issue approximately 7.76m shares of its common stock and pay $20m in cash to Akoya shareholders. Each Akoya share will receive $0.38 per share in cash and 0.1461 shares of Quanterix common stock. “Liquid biopsy will eventually surpass the market size of all other diagnostics testing combined. Enabling early disease detection, before symptoms appear, using non-invasive methods is our mission and will be the majority of Quanterix's long-term value," Masoud Toloue, Quanterix CEO.